PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

New report investigates pharma's global reach and impact

A report by the Access to Medicine Foundation examines how 20 major pharmaceutical companies are addressing patient access in low- and middle-income countries (LMICs), highlighting progress and areas needing improvement. The report identifies 42 different approaches to measuring patient reach, with 19 companies actively tracking this, but no industry-wide consensus. It calls for clearer, more actionable commitments to ensure lifesaving products reach underserved populations, emphasizing the need for collaboration and refining measurement methods to address health inequities.
statnews.com
·

Breakthrough therapies have given Duchenne muscular dystrophy families like mine hope

Recent FDA approvals of three new therapies for Duchenne muscular dystrophy have increased hope but also confusion among families. The lack of long-term data on gene therapy, especially in older and nonambulatory patients, and the potential for future treatment ineligibility due to antibody creation, adds to the complexity of decision-making. Families need better guidance from neurologists on therapy priorities and polypharmacy, as well as support to make informed decisions without judgment.
globenewswire.com
·

Monoclonal Antibodies Market to Reach USD 804.7 Billion By

The Global Monoclonal Antibodies Market is projected to grow from USD 279.8 billion in 2024 to USD 804.7 billion by 2033, at a CAGR of 12.5%. North America is expected to dominate with a 47.5% share in 2024, driven by strong healthcare infrastructure and high R&D investments. Oncology is projected to lead the application segment with a 46.2% share. Major companies include Roche, Novartis, Johnson & Johnson, Pfizer, and Merck.
biospace.com
·

Terns Shares Climb as Investigational GLP-1 Pill Spurs 5% Weight Loss After 28 Days

Terns Pharmaceuticals’ oral GLP-1R agonist, TERN-601, achieved 4.9% mean weight loss in a Phase I trial, outperforming competitors like Eli Lilly’s orforglipron and Pfizer’s danuglipron. The drug was well-tolerated, with no treatment-related dose interruptions. Terns plans to advance TERN-601 into Phase II in 2025.
quantisnow.com
·

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

Geron Corporation appoints Jim Ziegler as Executive VP, Chief Commercial Officer to lead global commercial strategy and drive growth of RYTELO™, effective September 9, 2024.
ascopost.com
·

Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer

Nivolumab plus gemcitabine/cisplatin chemotherapy significantly improved response rates, overall survival, and progression-free survival in patients with lymph node–only metastatic urothelial carcinoma, according to a post hoc analysis of the CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.
biospace.com
·

The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's

Despite declining use of Sanofi/Regeneron’s Dupixent due to competition from LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments for atopic dermatitis is rising, according to Spherix Global Insights. Dermatologists estimate that two-fifths of adult atopic dermatitis patients now receive advanced systemic treatments, highlighting the demand for effective AD treatments. The potential approvals of Galderma’s nemolizumab and Eli Lilly’s lebrikizumab could further shift physician preferences, with nemolizumab expected to gain more adoption than lebrikizumab.
genengnews.com
·

Phage Therapy's Neglected Potential Is Finally Being Realized

Phage therapy, recognized over 100 years ago, is making a comeback for treating antibiotic-resistant infections and other diseases. Advances include CRISPR engineering, AI-mediated methodologies, and naturally evolved phages. Companies like Locus Biosciences and Phiogen are developing optimized phage cocktails and off-the-shelf products. Trobix Bio uses nonlytic phages to deliver therapeutic payloads into bacteria for treating cancer and inflammatory diseases. Tolka AI Therapeutics integrates AI for scalable phage therapy design and manufacturing, targeting complex pathogens like Mycobacterium abscessus.

Brigham-Led Study Finds Weight Loss Drug Semaglutide Reduced COVID-19 Related ...

Semaglutide injections reduced overall, cardiovascular, and infection-related deaths by 19%, 15%, and 23% respectively in a study of 17,000 obese and overweight patients with heart disease.
finance.yahoo.com
·

Monoclonal Antibodies Market to Reach USD 804.7 Billion By 2033, Driven by ...

Global Monoclonal Antibodies Market to reach USD 804.7 billion by 2033, growing at a CAGR of 12.5% from USD 279.8 billion in 2024. Dominated by North America, human-derived antibodies, and oncology applications, with key players including Roche, Novartis, and Johnson & Johnson.
© Copyright 2024. All Rights Reserved by MedPath